Stocktoria
20/20 Biolabs, Inc. AIDX
20/20 Biolabs, Inc. financials (annual)
Bars are annual figures from 2024 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | $2.0M | $1.8M |
| Gross profit | $604,541 | $360,311 |
| R&D expense | $592,569 | $1.3M |
| SG&A expense | $3.3M | $4.8M |
| Operating income | -$3.3M | -$5.7M |
| Net income | -$3.7M | -$5.6M |
| EPS (diluted) | $-0.76 | $-1.16 |
| Operating cash flow | -$1.9M | -$2.6M |
| Cash & equivalents | $1.0M | $1.8M |
| Inventory | $116,217 | $47,164 |
| Total assets | $4.1M | $3.6M |
| Total liabilities | $4.2M | $2.1M |
| Shareholders' equity | -$19,225 | $1.5M |
Growth · year-over-year · Revenue CAGR 16.7%
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue growth | +16.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.